A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Conditions: NSCLC Interventions: Drug: BPI-1178; Drug: Osimertinib Sponsors: National Cancer Center, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials